Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exa...(a U.S.-based pharmaceutical company with...),Health

Date:8/27/2009

a U.S.-based pharmaceutical company with a long track record of building partnerships and developing and marketing products that make a positive difference in people's lives. In addition to its well-established franchises in therapeutic areas of the central nervous and cardiovascular systems, Forest's current pipeline includes product candidates in all stages of development and across a wide range of therapeutic areas. The company is headquartered in New York, NY. To learn more about Forest Laboratories, visit www.FRX.com.

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and any subsequent SEC filings.

    For further information
    Nycomed
    Media:
    General phone: +1 917 968 9795

    Forest Laboratories, Inc.
    Frank J. Murdolo, phone: +1 212 224 6714
    Vice President - Investor Relations
    Frank.Murdolo@frx.com

Notes to editors

Further details for the four trials will be presented at the European Respiratory Society Annual Congress 2009, in Vienna, Austria, September 12 to 16, 2009.

12-Month Trials

The two replicate, 12-month trials were randomised, placebo controlled and double blind. One 12 month study was conducted in 246 centres in 10 countries and the second was conducted in 221 centres in eight countries.

COPD patient
'/>"/>

SOURCE Nycomed Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
2. Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss
3. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
4. PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving COPD Therapies
5. Infant Formula Company Teams With the University of Virginia Pediatrics Department to Conduct Clinical Studies
6. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
7. School of Dentistry Studies Link Between Oral Health and Memory
8. Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells
9. New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring
10. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
11. Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery